Physician profile
Douglas Moore
NPI 1376512756
$1,273.56
in general payments reported to CMS, 2019-2025
23 companies · $78.37 in 2025
The $78.37 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $190 · 2021: $23.23 · 2022: $66.97 · 2023: $22.01 · 2024: $35.76 · 2025: $78.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $177.19 | 2019-2024 | Airsupra |
| Amgen INC. | $130.95 | 2019-2020 | |
| Boston Scientific Corporation | $112.65 | 2021-2025 | Watchman Flx, Watchman Access System |
| Abbvie INC. | $92.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $90.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $86.52 | 2019-2021 | |
| Pfizer INC. | $81.71 | 2019-2022 | |
| Novo Nordisk INC | $68.07 | 2019-2020 | |
| Lilly USA, LLC | $52.21 | 2019-2025 | Mounjaro, Zepbound |
| Ironshore Pharmaceuticals INC. | $51.02 | 2019 | |
| Therapeuticsmd, INC. | $33.98 | 2022 | |
| Genentech USA, INC. | $30.22 | 2019 | |
| Allergan, INC. | $28.26 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $25.75 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.31 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $22.00 | 2019 | |
| Daiichi Sankyo INC. | $15.63 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.46 | 2019 | |
| Amarin Pharma, INC. | $13.61 | 2019 | |
| Sanofi Pasteur INC. | $12.86 | 2019 | |
| Medtronic USA, INC. | $11.90 | 2019 | |
| Merck Sharp & Dohme LLC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.